ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ボラパキサル

Vorapaxar

HCID 10077130
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
618385-01-6
標準SMILES
CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1
InChIKey
ZBGXUVOIWDMMJE-QHNZEKIYSA-N
分子式
C29H33FN2O4
平均分子量
492.6 g/mol
単同位体質量
492.2424357

概要

Vorapaxar is a carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethynyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation. It has a role as a cardiovascular drug, a platelet aggregation inhibitor and a protease-activated receptor-1 antagonist. It is a carbamate ester, a lactone, a member of pyridines, an organofluorine compound and a naphthofuran. It is a conjugate base of a vorapaxar(1+).

名称と識別子

優先名称
Vorapaxar
IUPAC
ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
現地名
ボラパキサル
英語名
Vorapaxar
分子式
C29H33FN2O4
分子量
492.58

名称と別名

Vorapaxar618385-01-6SCH-530348SCH530348ZCE93644N2CHEBI:82702DTXSID201009336ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-dodecahydronaphtho[2,3-c]furan-6-yl]carbamatevorapaxarumethyl N-((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(5-(3-fluorophenyl)pyridin-2-yl)ethenyl)-1-methyl-3-oxo-dodecahydronaphtho(2,3-c)furan-6-yl)carbamateethyl N-((3R,3aS,4S,4aR,7R,8aR,9aR)-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)ethenyl)-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-naphtho(6,7-c)furan-7-yl)carbamateethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-naphtho[6,7-c]furan-7-yl]carbamate
名称をさらに表示
ボラパキサルボラパクサール3α-メチル-7β-(エトキシカルボニルアミノ)-4β-[2-[3-(3-フルオロフェニル)ピリジン-6-イル]エテニル]-1,3,3aα,4,4aβ,5,6,7,8,8aα,9,9aα-ドデカヒドロナフト[2,3-c]フラン-1-オンボラパキサールN-[1,3,3aα,4,4aβ,5,6,7,8,8aα,9,9aα-ドデカヒドロ-1-オキソ-3α-メチル4β-[2-[5-(3-フルオロフェニル)ピリジン-2-イル]エテニル]-ナフト[2,3-c]フラン-7β-イル]カルバミド酸エチル

物性

構造計算による物性

XLogP
5.3
極性表面積
77.5 Ų
水素結合供与体数
1
水素結合受容体数
6
回転可能結合数
6
重原子数
36
形式電荷
0
複雑度
821

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Blood and blood forming organs -> Antithrombotic agents

物理化学的性質

沸点
676 · 676.0±55.0 °C(Predicted)
比重(密度)
1.24 · 1.24±0.1 g/cm3(Predicted)
貯蔵温度
-20 ° · Store at -20° C
溶解性
24.65 mg/mL · ≥24.65 mg/mL in DMSO; insoluble in H2O; ≥10.64 mg/mL in EtOH with ultrasonic
外見
solid
酸解離定数(Pka)
12.49 · 12.49±0.60(Predicted)
色
White to off-white
InChIKey
ZBGXUVOIWDMMJE-QHNZEKIYSA-N
SMILES
C(OCC)(=O)N[C@@H]1CC[C@]2([H])[C@@]([H])(C1)C[C@@]1([H])C(=O)O[C@H](C)[C@@]1([H])[C@H]2/C=C/C1=NC=C(C2=CC=CC(F)=C2)C=C1

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H371 (66.7%): May cause damage to organs [Warning Specific target organ toxicity, single exposure]

P260, P264, P270, P273, P308+P316, P319, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesSTOT SE 2 (66.7%)

毒性情報

Hepatotoxicity · 1 件

Vorapaxar is associated with a low rate of serum enzyme elevations during therapy that was similar to the rate that occurred with placebo or comparator therapies. In a large controlled trial in over 10,000 patients monitored over a 2 year period, ALT elevations above 5 times the upper limit of normal occurred in 1% of vorapaxar vs 1.4% of placebo patients. In pooled analyses of laboratory studies from more than 39,000 patients receiving vorapaxar or placebo, GGT was the only liver test that was abnormal in a higher proportion of patients receiving vorapaxar (3.8%) than placebo (3.3%), and there were no reports of liver related serious adverse events or clinically apparent liver injury. Thus, liver injury from vorapaxar must be rare, if it occurs at all.

安全データ

wgk
WGK 3
Hazard Classifications
Aquatic Acute 1Aquatic Chronic 1
ストレージクラス
11 - Combustible Solids

化学と産業

薬理情報

ATC Code · 2 件

B - Blood and blood forming organs

QB - Blood and blood forming organs

Protein BindingVorapaxar is extensively bound (>99%) to human plasma proteins, such as human serum albumin.
Mechanism of Action · 1 件

Vorapaxar inhibits platelet aggregation through the reversible antagonism of protease-activated receptor 1 (PAR-1), also known as thrombin receptor. PARs are a family of G-protein coupled receptors highly expressed on platelets and activated by serine protease activity of thrombin to mediate thrombotic response. By blocking PAR-1 activating, vorapaxar inhibits thrombin-induced platelet aggregation and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation. Vorapaxar does not inhibit platelet aggregation induced by other agonists such as adenosine diphosphate (ADP), collagen or a thromboxane mimetic.

Biological Half-LifeVorapaxar has an effective half life of 3-4 days and an apparent terminal half life of 8 days.
Metabolism/MetabolitesVorapaxar is metabolized to its major circulating metabolite, M20, and its predominant metabolite excreted into feces, M19, by CYP3A4 and CYP 2J2.
FDA Pharmacological Classification · 5 件

ZCE93644N2

VORAPAXAR

Established Pharmacologic Class [EPC] - Protease-activated Receptor-1 Antagonist

Mechanisms of Action [MoA] - Protease-activated Receptor-1 Antagonists

Vorapaxar is a Protease-activated Receptor-1 Antagonist. The mechanism of action of vorapaxar is as a Protease-activated Receptor-1 Antagonist.

MeSH Pharmacological Classification · 1 件

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

関連反応

0 件
反応記録を作成
関連する反応はまだありません

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
ボラパキサー
エチル N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{2-[5-(3-フルオロフェニル)ピリジン-2-イル]エテニル}-1-メチル-3-オキソ-ドデカヒドロナフト[2,3-c]フラン-6-イル]カルバマート
MK-5348
Vorapaxar (SCH 530348)
[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-carbamic acid ethyl ester
CS-2015
CS-1663
Voarapaxar
2H5]-Vorapaxar
7-Dihydrocapsaicin
RefChem:56276B01AC26DTXCID801436165Vorapaxar free baseMFCD16038876UNII-ZCE93644N2ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamateCHEMBL493982

データベース識別子

CAS
618385-01-6
PubChem CID
10077130
DTXSID
DTXSID201009336
ChEMBL
CHEMBL493982
ChEBI
CHEBI:82702
UNII
ZCE93644N2
EC Number
612-523-7
Nikkaji
J2.419.474D、J2.933.500A
Absorption, Distribution and Excretion · 3 件

After oral administration, vorapaxar is rapidly absorbed and peak concentrations occur at a median tmax of 1 hour under faster conditions. Vorapaxar may be taken with or without food as ingestion with a high-fat meal did not result in meaningful changes in AUC. The mean absolute bioavailability is 100%.

Vorapaxar is primarily eliminated as its metabolite M19 through the feces (91.5%), and partially eliminated in the urine (8.5%).

424 L

応用分野 · 1 件

説明Vorapaxar is an orally bioavailable competitive antagonist of the proteinase-activated receptor (PAR1; Ki = 8.1 nM), also known as the thrombin receptor. It is selective for PAR1 over other PARs, as well as a number of GPCRs, ion channels, and receptors. It inhibits platelet aggregation induced by thrombin and haTRAP (IC50s = 47 and 25 nM, respectively). Vorapaxar (0.1 mg/kg, i.v.) completely inhibits platelet aggregation in cynomolgus monkeys ex vivo. Formulations containing vorapaxar are used in the prevention of thrombotic cardiovascular events.

補足説明 · 1 件

定義ChEBI: A carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethyny }-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation.